Generative AI And How We Can Harness Its Power In Clinical Development

By Thomas Pietsch, Global Head of Scientific Data Technology and AI

Between 2016 and 2020, the FDA’s CDER saw a gradual increase in AI and machine learning submissions, with a sharp rise to 132 submissions in 2021. This surge, predating ChatGPT’s debut, marks a pivotal moment in integrating AI into drug discovery and development. AI’s potential spans various applications, from search-and-retrieve and content generation to workflow automation.

Parexel has been at the forefront, investing in AI solutions to enhance clinical development efficiency. Their recent launch of ParexelGPTTM and a robust AI framework exemplifies their commitment to responsible AI use, ensuring human oversight and adherence to best practices. Explore how AI is transforming clinical research and the innovative strides Parexel is making in this dynamic field.

Read the full piece to understand the intricacies and future implications of AI in biopharma.